|
|
|
Volumn 41, Issue 1, 2000, Pages
|
|
Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology;Zulassung für rekombinanten Wachstumsfaktor. Patienten mit diabetischen Fussulzera können seit Januar 2000 mit dem gentechnisch hergestellten Wachstumsfaktor Becaplermin (Regranex) behandelt werden.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PLATELET DERIVED GROWTH FACTOR;
PLATELET DERIVED GROWTH FACTOR BB;
PLATELET-DERIVED GROWTH FACTOR BB;
RECOMBINANT PROTEIN;
ARTICLE;
DIABETIC FOOT;
DRUG EFFECT;
HUMAN;
WOUND HEALING;
DIABETIC FOOT;
HUMANS;
PLATELET-DERIVED GROWTH FACTOR;
RECOMBINANT PROTEINS;
WOUND HEALING;
|
|
EID: 0033628670
PISSN: 00209554
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
